182 related articles for article (PubMed ID: 22382876)
1. Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.
Staff C; Magnusson CG; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frödin JE; Wahrén B; Mellstedt H; Ullenhag GJ
J Clin Immunol; 2012 Aug; 32(4):855-65. PubMed ID: 22382876
[TBL] [Abstract][Full Text] [Related]
2. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.
Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
Cancer Immunol Immunother; 1998 Nov; 47(3):131-42. PubMed ID: 9829838
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
7. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.
Ullenhag GJ; Frödin JE; Strigård K; Mellstedt H; Magnusson CG
Cancer Res; 2002 Mar; 62(5):1364-9. PubMed ID: 11888906
[TBL] [Abstract][Full Text] [Related]
8. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Marshall JL; Hoyer RJ; Toomey MA; Faraguna K; Chang P; Richmond E; Pedicano JE; Gehan E; Peck RA; Arlen P; Tsang KY; Schlom J
J Clin Oncol; 2000 Dec; 18(23):3964-73. PubMed ID: 11099326
[TBL] [Abstract][Full Text] [Related]
9. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.
Conry RM; Allen KO; Lee S; Moore SE; Shaw DR; LoBuglio AF
Clin Cancer Res; 2000 Jan; 6(1):34-41. PubMed ID: 10656429
[TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).
Lima J; Jenkins C; Guerrero A; Triozzi PL; Shaw DR; Strong TV
Vaccine; 2005 Jan; 23(10):1273-83. PubMed ID: 15652670
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
[TBL] [Abstract][Full Text] [Related]
12. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients.
Ragnhammar P; Friesen HJ; Frödin JE; Lefvert AK; Hassan M; Osterborg A; Mellstedt H
Blood; 1994 Dec; 84(12):4078-87. PubMed ID: 7994026
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human monoclonal igA antibody against CEA to recruit neutrophils to CEA-expressing cells.
Zhao J; Kuroki M; Shibaguchi H; Wang L; Huo Q; Takami N; Tanaka T; Kinugasa T; Kuroki M
Oncol Res; 2008; 17(5):217-22. PubMed ID: 18980018
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.
Hallermalm K; Johansson S; Bråve A; Ek M; Engström G; Boberg A; Gudmundsdotter L; Blomberg P; Mellstedt H; Stout R; Liu MA; Wahren B
Scand J Immunol; 2007 Jul; 66(1):43-51. PubMed ID: 17587345
[TBL] [Abstract][Full Text] [Related]
16. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.
Staff C; Mozaffari F; Haller BK; Wahren B; Liljefors M
Vaccine; 2011 Sep; 29(39):6817-22. PubMed ID: 21195077
[TBL] [Abstract][Full Text] [Related]
17. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
18. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
19. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Arlen P; Tsang KY; Marshall JL; Chen A; Steinberg SM; Poole D; Hand PH; Schlom J; Hamilton JM
Cancer Immunol Immunother; 2000 Dec; 49(10):517-29. PubMed ID: 11129322
[TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
